Barclays Cuts Avantor (NYSE:AVTR) Price Target to $23.00

Avantor (NYSE:AVTR) had its price target reduced by Barclays from $26.00 to $23.00 in a research note published on Monday,Benzinga reports. Barclays currently has an overweight rating on the stock.

Several other brokerages also recently weighed in on AVTR. UBS Group restated a “neutral” rating and issued a $25.00 target price (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Raymond James lowered their target price on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. Wells Fargo & Company lowered their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Finally, Robert W. Baird lowered their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $26.15.

Avantor Stock Performance

Shares of AVTR stock opened at $18.06 on Monday. The firm has a market cap of $12.29 billion, a price-to-earnings ratio of 39.26, a PEG ratio of 3.87 and a beta of 1.28. The company’s 50 day moving average is $21.63 and its 200 day moving average is $23.39. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. Avantor has a 52-week low of $18.00 and a 52-week high of $28.00.

Avantor (NYSE:AVTR) last announced its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period in the prior year, the business earned $0.22 earnings per share. On average, sell-side analysts anticipate that Avantor will post 0.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. MassMutual Private Wealth & Trust FSB lifted its position in Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after purchasing an additional 625 shares during the period. Smartleaf Asset Management LLC lifted its position in Avantor by 106.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock valued at $34,000 after purchasing an additional 830 shares during the period. UMB Bank n.a. acquired a new position in Avantor during the third quarter valued at $49,000. Global Retirement Partners LLC lifted its position in Avantor by 76.7% during the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock valued at $52,000 after purchasing an additional 1,067 shares during the period. Finally, Nisa Investment Advisors LLC lifted its position in Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after purchasing an additional 835 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.